A synergistic therapy strategy for hypoxic solid tumor therapy

Abstract

Photodynamic therapy (PDT) has been considered an effective treatment for various types of cancers. However, hypoxic microenvironment within the solid tumor is averse to oxygen-involved PDT, resulting in low therapeutic efficacy. This Preview highlights a recent study regarding a synergistic therapy that combines PDT and chemotherapy, in which hypoxic solid tumor diagnosis imaging and therapy can be achieved. Photodynamic therapy (PDT) has been considered an effective treatment for various types of cancers. However, hypoxic microenvironment within the solid tumor is averse to oxygen-involved PDT, resulting in low therapeutic efficacy. This Preview highlights a recent study regarding a synergistic therapy that combines PDT and chemotherapy, in which hypoxic solid tumor diagnosis imaging and therapy can be achieved. Engineering a theranostic platform for synergistic hypoxia-responsive photodynamic therapy and chemotherapyXiong et al.MatterMarch 11, 2022In BriefA molecular theranostic (DHQ-Cl-Azo) integrating hypoxia-responsive photodynamic therapy and chemotherapy, as well as NIR fluorescence surveillance, was reported. The agent serves as a novel heavy-atom-free photosensitizer via intersystem crossing. Thus, PDT could be operated in the normoxic tumor cells on the surface of solid tumors, and hypoxia-activatable chemotherapy was triggered in the hypoxic center of solid tumors. Through dual-mode therapies in different regions of a solid tumor with DHQ-Cl-Azo, good treatment efficacies for solid tumors have been achieved. Full-Text PDF